VS, Radhakrishnan http://orcid.org/0000-0001-9484-5669
D, Podder
H, Mukherjee
P, Mandal
R, Achari
S, Sen
D, Dey
I, Arun
Z, Latif
N, Arora
A, Nag
J, Kumar
R, Javed
SJ, Bhave
M, Parihar
DK, Mishra
M, Chandy
R, Nair
Article History
Received: 28 January 2021
Accepted: 1 May 2021
First Online: 18 May 2021
Declarations
:
: <b>Prof Nair R</b> has received research grants, advisory board fees as well as Speaker fee from Cipla, Freisenius Kabi, Johnson and Johnson, Mylan, Novartis, and Dr Reddy’s Laboratory. <b>Dr. RADHAKRISHNAN V</b> reports advisory fees (institutional) and non-financial Institutional support from PFIZER, Institutional grants and non-financial support from INTAS Pharmaceuticals, Institutional grants from NATCO Pharmaceuticals, Institutional grants from ROCHE, Institutional grants from BMS, Institutional grants and non-financial support from CIPLA Pharmaceuticals, Institutional grants from EMCURE, personal fees (institutional) from ASTRA ZENECA, non-financial institutional support from Dr. REDDY’s Laboratories, outside the submitted work. Other authors declare no relevant conflicts of interest with respect to the submitted work.
: Institutional Review Board (Ethics Committee) waiver number; EC/WV/TMC/58/20. Retrospective study with no patient personal identifiers.